| Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells X Zhu, M Badawi, S Pomeroy, DS Sutaria, Z Xie, A Baek, J Jiang, ... Journal of extracellular vesicles 6 (1), 1324730, 2017 | 449 | 2017 |
| Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia R Lapalombella, Q Sun, K Williams, L Tangeman, S Jha, Y Zhong, ... Blood, The Journal of the American Society of Hematology 120 (23), 4621-4634, 2012 | 373 | 2012 |
| Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10 JL Voorhees, AJ Tarr, ES Wohleb, JP Godbout, X Mo, JF Sheridan, ... PloS one 8 (3), e58488, 2013 | 269 | 2013 |
| Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1–mediated lipogenesis F Geng, X Cheng, X Wu, JY Yoo, C Cheng, JY Guo, X Mo, P Ru, B Hurwitz, ... Clinical Cancer Research 22 (21), 5337-5348, 2016 | 262 | 2016 |
| MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells K Joshi, Y Banasavadi-Siddegowda, X Mo, SH Kim, P Mao, C Kig, ... Stem cells 31 (6), 1051-1063, 2013 | 221 | 2013 |
| Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress X Cheng, F Geng, M Pan, X Wu, Y Zhong, C Wang, Z Tian, C Cheng, ... Cell metabolism 32 (2), 229-242. e8, 2020 | 187 | 2020 |
| Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma F Yan, L Alinari, ME Lustberg, L Katherine Martin, HM Cordero-Nieves, ... Cancer research 74 (6), 1752-1765, 2014 | 175 | 2014 |
| AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt–MDM2–Foxo3a signaling axis CC Chou, KH Lee, IL Lai, D Wang, X Mo, SK Kulp, CL Shapiro, CS Chen Cancer research 74 (17), 4783-4795, 2014 | 174 | 2014 |
| Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals R Lapalombella, YY Yeh, L Wang, A Ramanunni, S Rafiq, S Jha, J Staubli, ... Cancer cell 21 (5), 694-708, 2012 | 171 | 2012 |
| Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia J Yu, Y Peng, LC Wu, Z Xie, Y Deng, T Hughes, S He, XK Mo, M Chiu, ... PloS one 8 (2), e55934, 2013 | 170 | 2013 |
| Canonical and atypical E2Fs regulate the mammalian endocycle HZ Chen, MM Ouseph, J Li, T Pécot, V Chokshi, L Kent, S Bae, M Byrne, ... Nature cell biology 14 (11), 1192-1202, 2012 | 170 | 2012 |
| Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine LE Arnold, RA DiSilvestro, D Bozzolo, H Bozzolo, L Crowl, S Fernandez, ... Journal of child and adolescent psychopharmacology 21 (1), 1-19, 2011 | 160 | 2011 |
| CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody FT Awan, R Lapalombella, R Trotta, JP Butchar, B Yu, DM Benson Jr, ... Blood, The Journal of the American Society of Hematology 115 (6), 1204-1213, 2010 | 150 | 2010 |
| Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway R Lapalombella, L Andritsos, Q Liu, SE May, R Browning, LV Pham, ... Blood, The Journal of the American Society of Hematology 115 (13), 2619-2629, 2010 | 146 | 2010 |
| Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia EM McWilliams, JM Mele, C Cheney, EA Timmerman, F Fiazuddin, ... Oncoimmunology 5 (10), e1226720, 2016 | 145 | 2016 |
| Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties S Rafiq, JP Butchar, C Cheney, X Mo, R Trotta, M Caligiuri, D Jarjoura, ... The Journal of Immunology 190 (6), 2702-2711, 2013 | 128 | 2013 |
| SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer EH Bell, AR Chakraborty, X Mo, Z Liu, K Shilo, S Kirste, P Stegmaier, ... Clinical Cancer Research 22 (10), 2396-2404, 2016 | 127 | 2016 |
| NKp80 defines a critical step during human natural killer cell development AG Freud, KA Keller, SD Scoville, BL Mundy-Bosse, S Cheng, Y Youssef, ... Cell reports 16 (2), 379-391, 2016 | 121 | 2016 |
| Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia YC Tseng, SK Kulp, IL Lai, EC Hsu, WA He, DE Frankhouser, PS Yan, ... Journal of the National Cancer Institute 107 (12), djv274, 2015 | 118 | 2015 |
| The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma HK Bid, DA Phelps, L Xaio, DC Guttridge, J Lin, C London, LH Baker, ... Molecular cancer therapeutics 15 (5), 1018-1028, 2016 | 101 | 2016 |
john C. ByrdDistinguished University Professor, The Ohio State University在 osumc.edu 的电子邮件经过验证
